News & Analysis
M&A Analysis: Is Johnson & Johnson’s $30B Acquisition of Actelion Overvalued?
M&A Analysis: Is Johnson & Johnson’s $30B Acquisition of Actelion Overvalued?
Evolution Infographics
Lonza Accelerates its “Healthcare Continuum” Strategy with $5.5B Acquisition of Capsugel
Lonza Accelerates its “Healthcare Continuum” Strategy with $5.5B Acquisition of Capsugel
Evolution Infographics
Drug Development IPO Analysis: Over $4.2B Raised Globally in Q4 2016 Despite Continued NASDAQ Decline
Drug Development IPO Analysis: Over $4.2B Raised Globally in Q4 2016 Despite Continued NASDAQ Decline
News & Analysis
Illumina’s NovaSeq Platform Targets the $100 Human Genome, but do they Risk Self-Cannibalisation?
Illumina’s NovaSeq Platform Targets the $100 Human Genome, but do they Risk Self-Cannibalisation?

Illumina utilised their showcase at the JP Morgan Conference to announce its new DNA sequencers, the NovaSeq 5000 and NovaSeq 6000, promising that by the end of the year the new machines

Evolution Infographics
Promising Autologous CAR-T Cell Therapies Stumble: is this the End, or Just the Beginning?
Promising Autologous CAR-T Cell Therapies Stumble: is this the End, or Just the Beginning?
Evolution Infographics
Blood of Their Blood: Young Blood Transfusions & The Business of Ageing
Blood of Their Blood: Young Blood Transfusions & The Business of Ageing
News & Analysis
As the Dust Settles on the Quintiles IMS Merger, which CRO will enter the Healthcare Analytics Space Next?
As the Dust Settles on the Quintiles IMS Merger, which CRO will enter the Healthcare Analytics Space Next?

In May 2016 a megamerger between Quintiles, the world’s largest CRO, and healthcare data and consultancy firm IMS was announced, with the combined company branded as Quintiles IMS. With a

Evolution Infographics
Cancer Immunotherapy: A Developmental Timeline & Examination of the Prior Art Paradox
Cancer Immunotherapy: A Developmental Timeline & Examination of the Prior Art Paradox
News & Analysis
Danaher Strengthens Molecular Diagnostics Portfolio with $4B Acquisition of Cepheid
Danaher Strengthens Molecular Diagnostics Portfolio with $4B Acquisition of Cepheid

Danaher has announced the acquisition of medical diagnostics company Cepheid, bolstering their presence in the Molecular Diagnostics market. Danaher Corporation will pay $53 per share in cash, a premium of

News & Analysis
Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?
Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?

Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation by Sanofi, as well

News & Analysis
2016 US Venture Capital Investment into Life Sciences Companies: An Analysis by Evolution Global
2016 US Venture Capital Investment into Life Sciences Companies: An Analysis by Evolution Global

In order to elucidate the focus of Venture Capital funding in the Biotechnology sector this year, Evolution Analysts have assessed the deals carried out by the Top 25 US Venture

News & Analysis
Bio-Techne enters Genomics market with $250M acquisition of Advanced Cell Diagnostics
Bio-Techne enters Genomics market with $250M acquisition of Advanced Cell Diagnostics

Bio-Techne Corporation have agreed to acquire California-based molecular pathology company Advanced Cell Diagnostics for $250 million in cash plus additional potential milestone payments of up to $75M. The acquisition marks